X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor (RdCVF) and one enzyme reducing oxidative stress. It is under phase 1/2 clinical development for the treatment of Retinitis Pigmentosa.
Lead Product(s): SPVN06
Therapeutic Area: Genetic Disease Product Name: SPVN06
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress used for the treatment of for the treatment of retinitis pigmentosa.
Lead Product(s): SPVN06
Therapeutic Area: Genetic Disease Product Name: SPVN06
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
Through the divestment, Tenpoint has acquired SparingVision's ex vivo GIRK technology. SparingVision will remain focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate.
Lead Product(s): SPVN20
Therapeutic Area: Genetic Disease Product Name: SPVN20
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Tenpoint Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment July 12, 2023
Details:
SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of cone photoreceptors.
Lead Product(s): SPVN06
Therapeutic Area: Genetic Disease Product Name: SPVN06
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Proceeds from the financing will be used to fund the first-in-human trials of the Company’s two lead gene-independent assets, SPVN06 and SPVN20, as well as the development of genome editing assets through its collaboration with Intellia Therapeutics.
Lead Product(s): SPVN06
Therapeutic Area: Genetic Disease Product Name: SPVN06
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jeito Capital
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 14, 2022
Details:
As part of this collaboration, Intellia will grant SparingVision exclusive rights to Intellia’s proprietary in vivo CRISPR/Cas9-based genome editing technology including SPVN50 for up to three ocular targets addressing diseases with significant unmet medical need.
Lead Product(s): SPVN50
Therapeutic Area: Ophthalmology Product Name: SPVN50
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Intellia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2021
Details:
Acquisition adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa. GAMUT’s lead product, now SPVN20, is a novel, mutation-agnostic gene therapy, which aims at restoring the function of dormant cone cells.
Lead Product(s): SPVN20
Therapeutic Area: Genetic Disease Product Name: SPVN20
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: GAMUT Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 20, 2021
Details:
Under the terms of the agreement, SparingVision SAS receives nonexclusive rights to AGTC’s PR1.7 promoter for use in the development of two non-competing products with an opportunity to obtain rights to use the promoter for one additional product in the future.
Lead Product(s): SPVN06
Therapeutic Area: Genetic Disease Product Name: SPVN06
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Agtc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 19, 2021
Details:
Proceeds from the financing will be primarily used to advance the development of SparingVision’s breakthrough treatment SPVN06 for the mutation-agnostic treatment of retinitis pigmentosa.
Lead Product(s): SPVN06
Therapeutic Area: Genetic Disease Product Name: SPVN06
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: 4BIO Capital
Deal Size: $51.9 million Upfront Cash: Undisclosed
Deal Type: Financing October 21, 2020
Details:
SPVN06 uses a gene therapy-based approach independent of mutated genes and by a single subretinal injection of proprietary neurotrophic factors, aims at stopping and preventing the degeneration of photoreceptors leading to blindness.
Lead Product(s): SPVN06
Therapeutic Area: Genetic Disease Product Name: SPVN06
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
